Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-Arm Open Label Phase II Trial of Cryoablation in Combination With Pembrolizumab or Avelumab in Patients With Metastatic Urothelial Carcinoma

NCT04701918 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04701918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04701918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-Arm Open Label Phase II Trial of Cryoablation in Combination With Pembrolizumab or Avelumab in Patients With Metastatic Urothelial Carcinoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 4, 2021
Completion date
December 1, 2025
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, metastatic urothelial carcinoma